---
title: "Eli Lilly's drug Olomorasib has received breakthrough therapy designation from the U.S. FDA"
description: "Eli Lilly's drug Olomorasib has received breakthrough therapy designation from the U.S. FDA"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/255938000.md"
published_at: "2025-09-04T10:47:10.000Z"
---

# Eli Lilly's drug Olomorasib has received breakthrough therapy designation from the U.S. FDA

Eli Lilly's drug Olomorasib has received breakthrough therapy designation from the U.S. FDA

### Related Stocks

- [LLY.US - Eli Lilly](https://longbridge.com/en/quote/LLY.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Eli Lilly (LLY) Builds $1.5 Billion Inventory of Weight-Loss Pill | Eli Lilly (LLY) has prepared a $1.5 billion inventory of its new weight-loss pill, Orforglipron, ahead of its anticipate | [Link](https://longbridge.com/en/news/276070062.md) |
| Eli Lilly and Company $LLY Shares Acquired by Assetmark Inc. | Assetmark Inc. increased its holdings in Eli Lilly and Company (NYSE: LLY) by 6.0% in Q3, owning 55,360 shares valued at | [Link](https://longbridge.com/en/news/275971336.md) |
| Forget AI stocks: This pharma giant is using AI to dominate drug discovery | And there's more than one way to monetize this technology. | [Link](https://longbridge.com/en/news/276017486.md) |
| Vertex Pharmaceuticals' Therapies for Kidney Diseases Could Diversify Long-Term Revenue Streams, Oppenheimer Says | Vertex Pharmaceuticals' Therapies for Kidney Diseases Could Diversify Long-Term Revenue Streams, Oppenheimer Says | [Link](https://longbridge.com/en/news/275926557.md) |
| Patient enrolment concludes in Senti Biosciences’ SENTI-202 Phase I trial | Senti Biosciences has completed patient enrolment in its Phase I trial for SENTI-202, a CAR NK cell therapy targeting re | [Link](https://longbridge.com/en/news/275740471.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.